There are currently five biologics licensed for severe asthma in adults: omalizumab binds to IgE at FcεRI binding site; mepolizumab and reslizumab both bind to IL-5; and benralizumab binds to IL-5 receptor α subunit and dupilumab, which binds to IL4 receptor α subunit, thus blocking both IL-4 and IL-13 signaling (Table 2). The gene discussed is IL5; the disease is asthma.